Dechra Pharmaceuticals plc (LON:DPH) has been assigned a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is GBX 1,733.50 ($22.57).
A number of equities research analysts have issued reports on DPH shares. Stifel Nicolaus reiterated a “hold” rating and issued a GBX 1,550 ($20.18) price target on shares of Dechra Pharmaceuticals plc in a research note on Tuesday, July 11th. N+1 Singer reiterated a “buy” rating and issued a GBX 1,666 ($21.70) price target on shares of Dechra Pharmaceuticals plc in a research note on Thursday, July 6th. Numis Securities Ltd reiterated an “add” rating and issued a GBX 1,890 ($24.61) price target on shares of Dechra Pharmaceuticals plc in a research note on Thursday, July 6th. Investec reiterated a “buy” rating and issued a GBX 1,840 ($23.96) price target on shares of Dechra Pharmaceuticals plc in a research note on Thursday, July 6th. Finally, Panmure Gordon reiterated an “under review” rating on shares of Dechra Pharmaceuticals plc in a research note on Thursday, April 20th.
In other news, insider Ian Page sold 134,500 shares of the firm’s stock in a transaction dated Wednesday, June 21st. The stock was sold at an average price of GBX 1,927 ($25.09), for a total transaction of £2,591,815 ($3,375,198.59).
Shares of Dechra Pharmaceuticals plc (DPH) traded up 0.33% during trading on Friday, hitting GBX 1816.00. The stock had a trading volume of 124,823 shares. The firm’s market capitalization is GBX 1.69 billion. Dechra Pharmaceuticals plc has a 1-year low of GBX 1,225.00 and a 1-year high of GBX 1,970.00. The stock’s 50-day moving average price is GBX 1,737.63 and its 200 day moving average price is GBX 1,699.30.
About Dechra Pharmaceuticals plc
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.
Receive News & Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related companies with MarketBeat.com's FREE daily email newsletter.